SCG - About the company
SCG is a series C company based in Singapore (Singapore), founded in 2017. It operates as a Developer of immunotherapies for pathogenic infections and cancers. SCG has raised $8.1M in funding, with a current valuation of $*****. The company has 3702 active competitors, including 1216 funded and 866 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of immunotherapies for pathogenic infections and cancers. The company targets the most common cancer-causing infections helicobacter pylori, human papillomavirus, and hepatitis B, and develops a broad and unique pipeline of T cell therapies, antibodies, and therapeutic vaccines against infections and to prevent and cure its associated cancers.
- Website
- www.scgcell.com
- Email ID
- *****@scgcell.com
- Phone Number
- +65 **********
- Registered Address
- DEPOT ROAD, Singapore, 109683
Key Metrics
Founded Year
2017
Location
Singapore, Singapore
Stage
Series C
Total Funding
$8.1M in 1 round
Latest Funding Round
Post Money Valuation
$***** as on Apr 05, 2023
Investors
Ranked
600th among 3702 active competitors
Employee Count
17 as on Sep 30, 2026
Similar Companies
Legal entities associated with SCG
SCG is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
SCG CELL THERAPY PTE. LTD. UEN: 201728785N , Singapore, Active | Oct 09, 2017 | - | - |
Sign up to download SCG's company profile
SCG's funding and investors
SCG has raised a total funding of $8.1M over 1 round. Its latest funding round was a Series C round on Apr 05, 2023 for $*****. 1 investor participated in its latest round. SCG has 5 institutional investors.
Here is the list of recent funding rounds of SCG:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 05, 2023 | 5531956 | Series C | 1047333 | 7954299 | 3475330 | 5182352 |
Access funding benchmarks and valuations. Sign up today!View details of SCG's funding rounds and investors
SCG's founders and board of directors
Founder? Claim ProfileSCG's Board of Directors
SCG's board has 11 active members. Wang Shuli, Ma Siu Ling, Protzer Ulrike and Karin Maria Wisskirchen are part of team and Zhang Ke, Zhang Qiong, Shen Jason, Karin Maria Wisskirchen, Yuen Hoi Kar Carol, Ma Siu Ling and Fumin Zhuo are independent board members.Here is the list of SCG's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 7y 4m | |
isbqwig | Team | - | Current | 5y 9m |
tnatoqe | Team | - | Current | 7y 7m |
myopidz | Team | - | Past | 1y 1m |
Independent board member | - | Current | 7y 4m | |
fdzmsiu | Independent board member | - | Current | 9y 1m |
d{ruxgx | Independent board member | - | Current | 6y 1m |
diwetth | Independent board member | - | Current | 9y 6m |
vay{hvb | Independent board member | - | Current | 4y 2m |
vanewyu | Independent board member | - | Current | 4y 2m |
hxygacw | Independent board member | - | Past | 5y 5m |
SCG's employee count trend
SCG has 17 employees as of Sep 26. Here is SCG's employee count trend over the years:
Uncover SCG's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
SCG's Competitors and alternates
Top competitors of SCG include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of SCG, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
600th | Developer of immunotherapies for pathogenic infections and cancers | $8.1M | 51/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on SCG's competitors? Click here to see the top ones
SCG's Investments and acquisitions
SCG has made no investments or acquisitions yet.
Reports related to SCG
Here is the latest report on SCG's sector:
News related to SCG
Filter this listMedia has covered SCG for 1 event in last 1 year, It was about company updates.
•
SCG Announces Presentation of Clinical Results of SCG142 in HPV-related Carcinoma at ESMO 2025 APACPR Newswire•Oct 18, 2025•SCG
•
SCG Cell Therapy Receives China NMPA Clearance for SCG101V IND ApplicationPR Newswire•Jul 08, 2025•SCG
•
SCG Announces Positive Clinical Data for SCG101 in HBV-Related Liver CancerPR Newswire•May 08, 2025•SCG
•
SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in SingaporeVietnam Investment Review•Dec 23, 2024•SCG, A*STAR
•
•
•
•
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancementSingapore Business Review•Apr 17, 2024•SCG, A*STAR
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about SCG
Explore our recently published companies
- Gibsonlaw - Unfunded company
- Ah Consulting - Unfunded company
- Haswellandco - Unfunded company
- Gridlocked - Unfunded company
- Goobo - Unfunded company
- Asmi - San Francisco based, 2025 founded, Unfunded company
